Myambutol (Ethambutol Hydrochloride)

Ethambutol blocks the arabinosyl transferase enzyme that is essential for building the mycobacterial cell wall. By preventing arabinogalactan synthesis, the drug exerts a bacteriostatic effect, limiting the replication of the tuberculosis bacteria and allowing the immune system and other drugs to clear the infection.

The dosage of Myambutol is individualized by the prescribing clinician based on factors such as patient weight, age, renal function, and the overall treatment regimen. Healthcare providers determine the appropriate amount and frequency according to established tuberculosis treatment guidelines.

The safety of ethambutol in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and clinicians weigh potential benefits against possible risks. Breastfeeding mothers should consult their physician before using Myambutol.

To request Myambutol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ethambutol differs from agents such as isoniazid or rifampicin by its mechanism—targeting cell‑wall arabinosyl transferase rather than mycolic acid synthesis or RNA polymerase. It is generally well‑tolerated but requires regular eye monitoring, whereas some alternatives have higher hepatotoxic or neurotoxic risk profiles.

Myambutol should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keeping the product in a dry, controlled environment helps maintain its stability and potency throughout its shelf life.

Myambutol is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole with a full glass of water and follow any specific timing instructions related to other anti‑tuberculosis medications.

The most serious adverse effects include optic neuritis, which can lead to permanent visual loss, and severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Hepatic dysfunction and acute interstitial nephritis are also rare but potentially life‑threatening complications that require immediate medical attention.

Myambutol is contraindicated in individuals with known hypersensitivity to ethambutol or any component of the formulation. Caution is advised for patients with pre‑existing optic nerve disease, severe renal impairment, or significant liver disease, and it should be avoided in those for whom visual monitoring is not feasible.